Last reviewed · How we verify
SGC001
At a glance
| Generic name | SGC001 |
|---|---|
| Sponsor | Beijing Sungen Biomedical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Research Study to Evaluate the Efficacy and Safety of SGC001 in Patients With Anterior Wall ST-Segment Elevation Myocardial Infarction (PHASE2)
- A Research Study to Evaluate the Safety and Preliminary Efficacy of SGC001 in Patients With Myocardial Infarction (PHASE1)
- A Research Study to Evaluate the Safety and Tolerability of SGC001 in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGC001 CI brief — competitive landscape report
- SGC001 updates RSS · CI watch RSS
- Beijing Sungen Biomedical Technology Co., Ltd portfolio CI